全文获取类型
收费全文 | 119篇 |
免费 | 11篇 |
专业分类
儿科学 | 1篇 |
基础医学 | 15篇 |
口腔科学 | 10篇 |
临床医学 | 5篇 |
内科学 | 58篇 |
特种医学 | 2篇 |
外科学 | 9篇 |
肿瘤学 | 30篇 |
出版年
2023年 | 1篇 |
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 4篇 |
2014年 | 7篇 |
2013年 | 3篇 |
2012年 | 10篇 |
2011年 | 6篇 |
2010年 | 7篇 |
2009年 | 3篇 |
2008年 | 4篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2005年 | 5篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 4篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 7篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有130条查询结果,搜索用时 15 毫秒
1.
Analyses of Genetic and Clinical Parameters for Screening Patients With Inherited Thrombocytopenia with Small or Normal‐Sized Platelets 下载免费PDF全文
Meri Ouchi‐Uchiyama MD PhD Yoji Sasahara MD PhD Atsuo Kikuchi MD PhD Kumiko Goi MD PhD Takaya Nakane MD PhD Mitsuru Ikeno MD PhD Yasushi Noguchi MD PhD Naokuni Uike MD PhD Yuji Miyajima MD PhD Kousaku Matsubara MD PhD Katsuyoshi Koh MD PhD Kanji Sugita MD PhD Masue Imaizumi MD PhD Shigeo Kure MD PhD 《Pediatric blood & cancer》2015,62(12):2082-2088
2.
Nobuyasu Hirai Kei Kasahara Hiroyuki Fujikura Shingo Yoshihara Taku Ogawa Yoshihiko Ogawa Naokuni Hishiya Yuki Suzuki Ryuichi Nakano Hisakazu Yano Masahide Yoshikawa Keiichi Mikasa 《Journal of infection and chemotherapy》2018,24(7):570-572
Mycotic aneurysm is a rare but life-threatening disease that warrants an integrated therapeutic approach involving surgical intervention and prolonged antibiotic use. However, the causative organisms are often unidentified because antibiotics started empirically render blood and tissue cultures negative. Molecular diagnosis has been reported to be useful in such culture-negative cases. We report a case of a culture-negative mycotic aortic aneurysm due to Haemophilus influenzae, diagnosed by direct 16S rRNA polymerase chain reaction (PCR) and sequencing of the resected aneurysm tissue. PCR for serotype revealed type b, and PCR and sequencing of the ftsI gene revealed alterations in penicillin-binding protein 3, suggesting resistance to ampicillin. Multilocus sequence typing demonstrated that the isolate belonged to sequence type 54. 相似文献
3.
Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study 下载免费PDF全文
Youko Suehiro Atsuhiko Hasegawa Tadafumi Iino Amane Sasada Nobukazu Watanabe Masao Matsuoka Ayako Takamori Ryuji Tanosaki Atae Utsunomiya Ilseung Choi Tetsuya Fukuda Osamu Miura Shigeo Takaishi Takanori Teshima Koichi Akashi Mari Kannagi Naokuni Uike Jun Okamura 《British journal of haematology》2015,169(3):356-367
Adult T cell leukaemia/lymphoma (ATL) is a human T cell leukaemia virus type‐I (HTLV‐I)‐infected T cell malignancy with poor prognosis. We herein developed a novel therapeutic vaccine designed to augment an HTLV‐I Tax‐specific cytotoxic T lymphocyte (CTL) response that has been implicated in anti‐ATL effects, and conducted a pilot study to investigate its safety and efficacy. Three previously treated ATL patients, classified as intermediate‐ to high‐risk, were subcutaneously administered with the vaccine, consisting of autologous dendritic cells (DCs) pulsed with Tax peptides corresponding to the CTL epitopes. In all patients, the performance status improved after vaccination without severe adverse events, and Tax‐specific CTL responses were observed with peaks at 16–20 weeks. Two patients achieved partial remission in the first 8 weeks, one of whom later achieved complete remission, maintaining their remission status without any additional chemotherapy 24 and 19 months after vaccination, respectively. The third patient, whose tumour cells lacked the ability to express Tax at biopsy, obtained stable disease in the first 8 weeks and later developed slowly progressive disease although additional therapy was not required for 14 months. The clinical outcomes of this pilot study indicate that the Tax peptide‐pulsed DC vaccine is a safe and promising immunotherapy for ATL. 相似文献
4.
The leucine twenty homeobox (LEUTX) gene,which lacks a histone acetyltransferase domain,is fused to KAT6A in therapy‐related acute myeloid leukemia with t(8;19)(p11;q13) 下载免费PDF全文
5.
6.
Delorme’s Procedure for Rectal Prolapse 总被引:5,自引:2,他引:3
Tsunoda A Yasuda N Yokoyama N Kamiyama G Kusano M 《Diseases of the colon and rectum》2003,46(9):1260-1265
PURPOSE: Clinical and physiological results of Delormes procedure were assessed retrospectively in patients undergoing this procedure for rectal prolapse.
METHODS: A consecutive series of 31 patients (7 males, 24 females; age, 14–93, mean 70 years) with full-thickness, rectal prolapse were treated by Delormes procedure between 1994 and 2002. Median follow-up was 39 (range, 6–96) months.
RESULTS: Good results were achieved in 27 patients (87 percent), prolapse recurrence was observed in 4 (13 percent), and mean recurrence time was 14 (range, 3–25) months. There were no postoperative deaths. Minor complications occurred in four patients. The median changes in preoperative and postoperative physiologic patterns in 16 patients were as follows: resting pressure from 21.0 (range, 5–48) to 23.5 (range, 12–76) cm H2O (P = 0.030), squeeze pressure from 64.0 (range, 27–248) to 108.0 (range, 32–264) cm H2O (P = 0.041), volume at first sensation from 100 (range, 70–180) to 70 (range, 40–130) ml (P = 0.002), maximum tolerated volume from 260 (range, 120–400) to 160 (range, 70–400) ml (P = 0.001). Incontinence improved in 63 percent. No patient became constipated, and 38 percent of those constipated preoperatively improved. The preoperative incontinence score improved from 11.5 (range, 1–20) to 6.0 (range, 0–20) after operation (P < 0.0001).
CONCLUSION: Delormes procedure had a low morbidity, did not lead to constipation, improved anal continence, and had a reasonably low recurrence rate. Improved anal sphincter and rectal sensation were associated with a reduced incidence of defecatory problems after Delormes procedure. 相似文献
7.
Katsumoto Y Aritake N Endoh A Ueda N Inami N 《Gan to kagaku ryoho. Cancer & chemotherapy》2011,38(12):2244-2246
We report three cases of patients in their eighties who received anti-EGFR antibody mono-therapy as first-line treatment for metastatic colorectal cancer. CASE 1: An 86-year-old woman who received cetuximab after a colostomy for unresectable rectal cancer with synchronous liver and lung metastases. Serum levels of CEA and CA19-9 showed a significant decrease at 2 months, after which they showed a gradual increase. Computed tomography (CT) revealed a reduction in the rectal tumor. CASE 2: An 82-year-old woman who received cetuximab for peritoneal metastases after a transverse colectomy. Serum levels of CEA and CA19-9 decreased to normal levels at 2 months, and CT imaging revealed disappearance of the tumor in the peritoneal cavity. CASE 3: A 79-year-old man who received panitumumab for lung, liver and para-aortic lymph node metastases after a descending colectomy. Serum levels of CEA and CA19-9 showed a decrease at 1 month, after which they showed a gradual increase. No marked change in the tumor was observed by CT. No change was observed in performance status or Vulnerable Elders Survey( VES-13) score, and the effect on overall condition was minimal. Grade 1-2 acneiform skin rash, paronychia, and desquamation, and grade 2-3 dry skin and pruritis were observed. More precise instructions on measures for dealing with skin rash are necessary to obtain higher drug compliance. 相似文献
8.
Tobinai K Igarashi T Itoh K Kurosawa M Nagai H Hiraoka A Kinoshita T Uike N Ogura M Nawano S Mori S Ohashi Y;IDEC-CB Study Group 《Cancer science》2011,102(9):1698-1705
Information regarding rituximab monotherapy with eight weekly infusions for relapsed or refractory indolent B cell non-Hodgkin lymphoma (B-NHL), in particular for patients pretreated with rituximab, is limited. To evaluate the efficacy and safety of eight doses of rituximab monotherapy, 52 patients with relapsed or refractory indolent B-NHL were enrolled in the present study. Forty of 45 eligible patients (89%) had follicular lymphoma and 24 (53%) were at intermediate or high risk group according to the Follicular Lymphoma International Prognostic Index. The median number of prior chemotherapy regimens was 1 (range 1-7). At the median follow-up of 12.2 months, the overall response rate (ORR), complete response rate (%CR), and median progression-free survival (PFS) were 69% (95% confidence interval [CI] 53%-82%), 47% (95% CI 32%-62%), and 15.6 months (95% CI 10.6- months), respectively. In the 33 patients pretreated with rituximab, the ORR, %CR, and median PFS were inferior compared with values for the 12 patients who had not received rituximab previously (64%vs 83% for ORR; 39%vs 67% for %CR; and 13.8 vs 17.5 months for median PFS, respectively). All mild-to-moderate infusion-related toxicities were reversible. Grade 3/4 non-hematologic adverse events occurred in six of the 52 patients. Two patients developed Grade 4 late-onset neutropenia and a decrease (>50%) in serum immunoglobulin was observed in six patients. In conclusion, rituximab monotherapy with eight weekly infusions is effective in relapsed patients with indolent B-NHL, with acceptable toxicities, including in patients pretreated with rituximab; however, careful monitoring is recommended for infections associated with late-onset neutropenia and hypogammaglobulinemia. (University Hospital Medical Information Network no. UMIN000002974.) 相似文献
9.
10.
Muta K Ohshima K Abe Y Uike N Choi I Matsushima T Nishimura J Kikuchi M Nakashima M Watanabe T Nawata H 《International journal of hematology》2004,79(4):340-344
In human cancer, RCAS1 (the receptor-binding cancer antigen expressed on SiSo cells) on the surface of various kinds of tumor cells reportedly induces the apoptosis of T-cells and natural killer cells, resulting in evasion of the immune system. In the present study, an immunohistochemical analysis of RCAS1 expression was performed with lymph node specimens obtained from patients with adult T-cell leukemia/lymphoma (ATLL). Positive staining was seen in 15 (75%) of 20 cases and in all cases of patients with short survival times. In the cases of B-cell lymphomas, positive staining was seen in only 1 (13%) of 8 cases. These findings indicate that expression of RCAS1 may be associated with the evasion from immune surveillance of cells infected with human T-lymphotropic virus type I, resulting in the development of overt leukemia/lymphoma. Determination of RCAS1 expression may be useful for predicting the prognosis of patients with ATLL. 相似文献